CD28 blockade induces division-dependent downregulation of interleukin-2 receptor alpha.

[1]  V. Krishnamurthi.  A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010 .

[2]  C. Larsen,et al.  Translating costimulation blockade to the clinic: lessons learned from three pathways , 2009, Immunological reviews.

[3]  A. Kirk,et al.  IFN-γ Dictates Allograft Fate via Opposing Effects on the Graft and on Recipient CD8 T Cell Responses1 , 2009, The Journal of Immunology.

[4]  A. Kirk,et al.  PD-1-Dependent Mechanisms Maintain Peripheral Tolerance of Donor-Reactive CD8+ T Cells to Transplanted Tissue , 2008, The Journal of Immunology.

[5]  A. Kirk,et al.  What's Next in the Pipeline , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Kirk,et al.  A Critical Precursor Frequency of Donor-Reactive CD4+ T Cell Help Is Required for CD8+ T Cell-Mediated CD28/CD154-Independent Rejection1 , 2008, The Journal of Immunology.

[7]  L. Lefrançois,et al.  Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells , 2007, Proceedings of the National Academy of Sciences.

[8]  C. Larsen,et al.  Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation , 2007, The Journal of experimental medicine.

[9]  A. Khoruts,et al.  Naïve and Memory CD4+ T Cell Survival Controlled by Clonal Abundance , 2006, Science.

[10]  J. Fechner,et al.  T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients , 2006, Transplantation.

[11]  P. Linsley,et al.  Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[13]  A. Abbas,et al.  IL-2 Induces a Competitive Survival Advantage in T Lymphocytes1 , 2004, The Journal of Immunology.

[14]  L. Lefrançois,et al.  IL-2 Is Not Required for the Initiation of CD8 T Cell Cycling but Sustains Expansion 1 , 2003, The Journal of Immunology.

[15]  T. Waldmann,et al.  Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. , 2003, Journal of autoimmunity.

[16]  R. Colvin,et al.  Campath‐1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  C. Larsen,et al.  The Role of the IL-2 Pathway in Costimulation Blockade-Resistant Rejection of Allografts1 , 2002, The Journal of Immunology.

[18]  S. Knechtle.  Treatment with immunotoxin. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[19]  Stephen P. Schoenberger,et al.  Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.

[20]  Susan M. Kaech,et al.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells , 2001, Nature Immunology.

[21]  C. Larsen,et al.  Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. , 1999, The Journal of clinical investigation.

[22]  H. Gudmundsdottir,et al.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.

[23]  G. Szot,et al.  Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. , 1997, Journal of immunology.

[24]  J. Soulillou,et al.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.

[25]  D. Harlan,et al.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Miller,et al.  The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. , 1992, Journal of immunology.

[27]  M. Jenkins,et al.  CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. , 1991, Journal of immunology.

[28]  G. Crabtree,et al.  Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. , 1991, Science.

[29]  C. Thompson,et al.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. , 1989, Science.

[30]  A. Kirk,et al.  IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses. , 2009, Journal of immunology.

[31]  F. Tedla.  Costimulation Blockade With Belatacept in Renal Transplantation , 2006 .

[32]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.